Michael Perretta

Cooley advised Kalshi, the first Commodity Futures Trading Commission-regulated exchange dedicated to trading on the outcome of future events, on its $300 million Series D financing, valuing the company at $5 billion.

Cooley advised Allay Therapeutics, a clinical-stage biotechnology company pioneering ultrasustained analgesic products to transform postsurgical pain management and recuperation, on its $57.5 million Series D financing.

Cooley advised Inventiva on its $107.7 million initial public offering of 7,478,261 American Depositary Shares or ADSs. Inventiva, whose securities now trade on the Nasdaq Global Market and Euronext Paris under the symbol “IVA,” is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need. Partners Div Gupta, Rich Segal, and Alison Haggerty led the Cooley team.

Cooley advised Bolt Biotherapeutics on its $264.50 million initial public offering of 13,225,000 shares of common stock, which includes the exercise in full of the underwriters’ option to purchase an additional 1,725,000 shares. Bolt Biotherapeutics, whose securities now trade on the Nasdaq Global Market under the symbol “BOLT,” is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Partners John McKenna and Sonya Erickson led the Cooley team.